Support women in science at Burnet Institute
Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
Donate today to support women in science at Burnet and their work to unlock the vaginal microbiome and reduce risk of HIV infection and preterm birth for women around the world.
OBJECTIVE: Scale-up of HIV pre-exposure prophylaxis (PrEP) has raised concerns regarding its impact on clinic capacity and access to HIV testing. We describe enrolment in PrEPX, a large PrEP implementation study in Victoria, Australia, and the impact of PrEP uptake and maintenance on existing health services. METHODS: We describe enrolment between 26 July 2016 and 31 March 2018 and trends in HIV testing among PrEPX participating and non-participating gay and bisexual and other men who have sex with men (GBM) at five study clinics participating in a sentinel surveillance system (ACCESS). We evaluated HIV and STI testing trends using segmented linear regression across the pre-study (January2015-June2016) and PrEPX study (July2016-March2018) periods. FINDINGS: 2049 individuals registered interest in study participation: 72% enrolled into the study. Study clinics enrolled participants rapidly; of 4265 people enrolled in PrEPX (98% GBM), 1000 enrolled by week-three, 88% (n=876) of whom enrolled at ACCESS sites.Pre-study period HIV testing rates were increasing at all ACCESS sites. In the month PrEPX commenced, there was an additional 247 HIV tests among PrEPX participants (p<0.01) and no significant change among non-PrEPX GBM (p=0.72). Across the study period, HIV testing increased by 7.2 (p<0.01) and 8.9 (p<0.01) tests/month among PrEPX participants and non-PrEPX GBM, respectively. HIV testing increased among non-PrEPX GBM at sexual health clinics (18.8 tests/month, p<0.01) and primary care clinics (7.9 tests/month, p<0.01). Similar trends were observed across testing for all measured STIs. CONCLUSIONS: Rapid PrEP scale-up is possible without a reduction in HIV testing among GBM not using PrEP.